Dalgety, a Midlands-based medicinal cannabis producer, has signed a contract agreement to enable the commercial supply of pharmaceutical-grade, THC-rich prescription medicines to the UK market.
The company has agreed on a deal with Grow Pharma and its licensed JV partner, IPS Pharma. Grow Pharma is a distributor of prescribed cannabis medicines, offering a suite of educational materials for healthcare professionals, as well as one-to-one advice, learning events, and prescription support for new doctors.
James Leavesley, chief operating officer at Dalgety, said: "We began discussions with Grow more than two years ago, and we share its ambition as a leader within the medical cannabis industry.
"From cultivation and processing through to patient experience, we're aligned in our aim of providing the highest quality medicine and service to patients. I'm excited to announce that this agreement has now come to fruition." In January this year, Dalgety was granted a Home Office license, allowing it to cultivate and manufacture EU-GMP grade high THC-medical cannabis from its UK-based facility.
Read more at insidermedia.com